Logo

Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Share this

Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Shots:

  • Janssen enters into an agreement to utilize Iktos’ AI (in silico drug design) technology for the enhancement of speed & efficacy of its small molecules discovery platform and will develop new therapies utilizing Iktos’ know-how in deep generative models applied to chemistry with its own AI expertise
  • Additionally- Iktos has also collaborated with other biopharma companies for its AI technology to expedite the design of compounds and plans to release its SaaS software Makya- a beta version for testing by customers in mid-2019
  • Iktos’ in silico drug design technology improves the drug discovery workflows by utilizing the existing data in designing molecules that are optimized in silico to meet the criteria of a small molecule discovery projects

Ref: Business Wire | Image: Janssen 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions